From Cost to Efficacy: Exploring Novel Biologics Treatment in Asthma Care

Many people are treated for severe, uncontrolled Asthma which is associated with a high risk of hospitalization. For some people with different types of Asthma was offered a new type of treatment alongside their usual asthma medicines - Monoclonal Antibodies, known as Biologics.

Join Dr. David Bull as he interviews Prof. Michael Wechsler from the National Jewish health hospital in Denver, USA, whose research focuses on novel Asthma therapy and biologics treatment for Asthma and related diseases and addresses the current challenges of Asthma care with the use of Biologics.

You will find out how treatment with biologics can improve symptoms of asthma and reduce asthma attacks, learn the differences between the biologics treatment and classic asthma treatment, and discover which groups of patients could likely be treated successfully with biologics therapy.

Stay in touch for further news from EUFOREA!

🌐 Visit our website: http://bit.ly/3qTanpG

➡️ Follow us on Facebook: http://bit.ly/3cnNyFF
➡️ Follow us on LinkedIn: http://bit.ly/2OqtWsf
➡️ Follow us on Twitter: http://bit.ly/38wrrM7
​
📌 EUFOREA is an international non-profit organization forming an alliance of all stakeholders dedicated to reduce the prevalence and burden of allergies and airway diseases through the implementation of optimal patient care through education, research and advocacy.
--------------------------------------------------------------------------------------------------------------------------
Subscribe to our YouTube Channel for our latest videos within Allergies and Airway Diseases
http://bit.ly/3eMvc3E
--------------------------------------------------------------------------------------------------------------------------
Get in touch with EUFOREA team for any questions
http://bit.ly/2OtlIQp

#EUFOREA